AptarGroup, Inc.

NYSE:ATR

Medical - Instruments & Supplies

Healthcare
$141.67 +0.55%

+$0.66 today

Market cap
$8.98B
Beta
0.40
P/E (TTM)
20.0
EPS (TTM)
$6.04
Dividend yield
1.57%
52W Low $103.23High $164.28

Volume 0.34M

Average 0.51M

ATR EBITDA Margin

EBITDA as a percentage of revenue.

AptarGroup, Inc.NYSE: ATR

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to 20.2%

EBITDA Margin was 20.2% in Q2 FY2026, down 2.6 pp from a year earlier. On a trailing-twelve-month basis it was 20.9%, down 1.5 pp year over year. Over 3 fiscal years it widened by 3.7 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 7 analysts of 20.6% for the fiscal year ending Dec 2026, down from 22.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
20.2%+1.3 pp QoQ
Last fiscal yearDec 2025
22.0%+0.3 pp YoY
LTMJun 2026
20.9%-1.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.6 pp-3.4 pp-0.8 pp
1 year+0.3 pp-1.4 pp-1.7 pp
3 years+3.7 pp-0.8 pp-4.5 pp
5 years+1.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
22.0%
Year-over-year change
+0.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How ATR compares with its peers on the latest reported figures

  • ATR's LTM Jun 2026 EBITDA Margin of 20.9% is the 3rd highest of the 7 companies compared; the peer median is 15.4%.
  • Its year-over-year change of -1.5 pp is the 5th highest of 7, against a peer median of +0.2 pp.
  • Over three fiscal years its change of +3.7 pp compares with a peer median of -0.3 pp.
ATR Competitors Peer median
EBITDA Margin for ATR and competitors
Company Period LTM level YoY 3-year change
WSTWest Pharmaceutical Services, Inc.LTM Jun 202626.2% +0.5 pp-2.9 pp
STVNStevanato Group S.p.A.LTM Jun 202624.3% -2.8 pp-0.4 pp
ATRAptarGroup, Inc.LTM Jun 202620.9% -1.5 pp+3.7 pp
TRSTriMas CorporationLTM Mar 202616.0% +3.3 pp-2.2 pp
AMCRAmcor plcLTM Jun 202614.8% +3.0 pp-0.1 pp
SLGNSilgan Holdings Inc.LTM Jun 202613.9% -0.0 pp+0.7 pp
SONSonoco Products CompanyLTM Sep 20269.8% -3.5 pp+5.5 pp
Peer median (excluding ATR) 15.4%+0.2 pp-0.3 pp

Competitors are the stored peer set for ATR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.23B3.32B3.49B3.58B3.78B
Cost of Revenue2.07B2.16B2.22B2.23B2.66B
Gross Profit1.16B1.16B1.26B1.36B1.12B
Gross Margin35.8%35.0%36.2%37.8%29.6%
Research & Development99.8M000105.1M
Selling, General & Admin551.24M544.26M565.78M582.23M499.94M
Operating Expenses809.34M784.57M859.38M859.01M605.04M
Depreciation & Amortization234.85M233.71M248.59M263.78M287.36M
EBITDA586.79M609.41M663.84M777.45M831.48M
EBITDA Margin18.2%18.3%19.0%21.7%22.0%
Operating Income347.35M379.27M404.02M496.5M512.34M
Operating Margin10.8%11.4%11.6%13.9%13.6%
Interest Income3.67M2.7M4.37M12.1M11.68M
Interest Expense30.28M40.83M40.42M43.9M52.74M
Other Income / Expenses(25.69M)(44.57M)(29.19M)(26.73M)(20.96M)
Income Before Tax321.66M334.7M374.83M469.77M491.38M
Pre-Tax Margin10.0%10.1%10.7%13.1%13.0%
Income Tax Expense78.02M95.15M90.65M95.59M98.88M
Net Income244.1M239.29M284.49M374.54M392.79M
Net Margin7.6%7.2%8.2%10.5%10.4%
EPS (Basic)3.723.664.345.655.97
EPS (Diluted)3.603.594.255.535.88
Weighted Avg Shares65.66M65.4M65.62M66.33M65.74M
Weighted Avg Shares (Diluted)67.68M66.72M66.91M67.69M66.72M

AptarGroup, Inc.

NYSE:ATR

Intrinsic Alpha fair value

Locked

Current Price

$141.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.